Amgen Announces Termination of Poison Pill Effective July 31, 2006
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 11, 2006--Amgen
(NASDAQ:AMGN) announced today that the company's board of directors
has voted unanimously to terminate the company's stockholder rights
plan, commonly referred to as a "poison pill." Originally scheduled to
expire on December 12, 2010, the plan has been amended to accelerate
the expiration date to July 31, 2006, effectively terminating the plan
as of that date.
Amgen's board has also established a policy providing for
stockholder approval for any future stockholder rights plan, either
prior to or within twelve months after adoption. The full text of the
policy will be available on the Corporate Governance page under the
"Investors" tab on Amgen's website at www.amgen.com.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (Media)
Arvind Sood, 805-447-1060 (Investors)